This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Synovis Life Technologies Reports 22 Percent Revenue Increase And Earnings Per Share Of $0.24 In Fiscal 2011 Fourth Quarter

Stocks in this article: SYNO

Synovis Life Technologies, Inc. (Nasdaq: SYNO), today reported its financial results for the fourth quarter and fiscal year ended October 31, 2011.

Yesterday, Synovis and Baxter International Inc., (NYSE:BAX) announced a definitive agreement for Baxter to acquire Synovis. The Synovis board of directors has unanimously approved the transaction and recommends that shareholders approve the agreement at an offer price of $28 per share, which equates to $325 million of equity value or approximately $260 million net of acquired cash, cash equivalents and investments. The offer price represents a 53 percent premium above Synovis’ average stock price of the four weeks prior to announcement. The transaction is expected to close in the first calendar quarter of 2012, subject to approval by Synovis’ shareholders, customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

For the fiscal fourth quarter, net revenue rose to a record $22.1 million, a 22 percent increase over $18.1 million in the year-ago period. Operating income totaled $4.2 million, an 86 percent gain over operating income of $2.2 million in the year-ago period. Net income for the fiscal 2011 fourth quarter was $2.7 million, or $0.24 per diluted share, compared to net income of $1.5 million, or $0.13 per diluted share, in the fiscal 2010 fourth quarter.

For the full fiscal year, net revenue rose to $82.4 million, up 20 percent from $68.6 million in fiscal 2010. Operating income for fiscal 2011 was $12.4 million, up 69 percent from operating income of $7.3 million last fiscal year. Net income was $8.5 million in fiscal 2011, or $0.73 per diluted share, compared to $4.9 million, or $0.43 per diluted share, in the previous fiscal year.

Conference Call CanceledGiven the acquisition announcement, Synovis Life Technologies has canceled its fourth quarter conference call which was scheduled for 10 a.m. CT today.

About Synovis Life TechnologiesSynovis Life Technologies, Inc., a diversified medical device company based in St. Paul, Minn., develops, manufactures and markets biological and mechanical products used by several surgical specialties to facilitate the repair and reconstruction of soft tissue damaged or destroyed by disease or injury. The company’s products include implantable biomaterials for soft tissue repair, devices for microsurgery and surgical tools – all designed to reduce risks and/or facilitate critical surgeries, improve patient outcomes and reduce healthcare costs. For additional information on Synovis Life Technologies and its products, visit the company’s website at www.synovislife.com .

Forward-looking statements contained in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements can be identified by words such as “should”, “could”, “may”, “will”, “expect”, “believe”, “anticipate”, “estimate”, “continue”, or other similar expressions. Certain important factors that could cause results to differ materially from those anticipated by the forward-looking statements made herein include whether and when the proposed acquisition by Baxter International, Inc. will be consummated, the timing of product introductions, the ability of the sales force to grow and sustain revenues, the impact of increased competition in various markets Synovis serves, the ability to grow Orthopedic and Wound revenue and achieve profitability, outcomes of clinical and marketing studies as well as regulatory submissions, the number of certain surgical procedures performed, the ability to identify, acquire and successfully integrate suitable acquisition candidates, any operational or financial impact from the current global economic environment, the impact of healthcare reform legislation, as well as other factors found in the Company’s filings with the Securities and Exchange Commission, such as the “Risk Factors” section in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 31, 2010.

   

SYNOVIS LIFE TECHNOLOGIES, INC.

 

Consolidated Statements of Income (unaudited)

(In thousands, except per share data)

 
Three Months Ended Twelve Months Ended
October 31, October 31,

2011

 

2010

2011

 

2010

 
Net revenue $ 22,053 $ 18,116 $ 82,363 $ 68,565
Cost of revenue 5,874 5,026 22,343 19,025
Gross margin 16,179 13,090 60,020 49,540
Gross margin percentage 73% 72% 73% 72%
 
Selling, general and administrative expenses 10,955 9,554 42,949 37,812
Research and development expenses 1,065 1,296 4,709 4,393
 
Operating expenses 12,020 10,850 47,658 42,205
 

Operating income

4,159

2,240

12,362

7,335

 
Interest income 83 73 311 284
 
Income before provision for income taxes 4,242 2,313 12,673 7,619
 
Provision for income taxes 1,527 833 4,212 2,743
 
Net income $ 2,715 $ 1,480 $ 8,461 $ 4,876
 
Basic earnings per share $ 0.24 $ 0.13 $ 0.74 $ 0.43
 
Diluted earnings per share $ 0.24 $ 0.13 $ 0.73 $ 0.43
 

Weighted average shares  outstanding - basic

11,344

11,284

11,381

11,262

Weighted average shares  outstanding - diluted

11,486

11,449

11,571

11,441

 

SYNOVIS LIFE TECHNOLOGIES, INC.

   
 

Consolidated Revenues (unaudited)

(In thousands)

 
Three Months Ended Twelve Months Ended
October 31, October 31,

2011

 

2010

2011

 

2010

 
Peri-Strips $ 6,614 $ 5,153 $ 23,675 $ 19,414
Tissue-Guard 4,970 4,221 18,407 16,550
Veritas 3,956 3,661 15,829 14,368
Microsurgery 4,326 3,123 15,190 11,020

Orthopedic and Wound

752 685 3,514 1,878
Surgical tools and other   1,435   1,273   5,748   5,335
Total Revenue $ 22,053 $ 18,116 $ 82,363 $ 68,565
 

Domestic

$

18,675

$

15,247

$

70,130

$

57,700

International   3,378   2,869   12,233   10,865
Total Revenue $ 22,053 $ 18,116 $ 82,363 $ 68,565
 
SYNOVIS LIFE TECHNOLOGIES, INC.    
 
Consolidated Balance Sheets
As of October 31, 2011 (unaudited) and October 31, 2010
(In thousands, except share and per share data)
October 31,

October 31,

2011

2010

ASSETS
Current assets:
Cash and cash equivalents $ 18,013 $ 12,951
Short-term investments 41,203 41,119
Accounts receivable, net 11,262 8,701
Inventories 9,998 9,433
Deferred income tax asset, net 447 367
Other current assets   1,973   1,715
Total current assets 82,896 74,286
 
Investments, net 7,335 7,854
Property, plant and equipment, net 4,154 3,401
Goodwill 3,620 3,620
Other intangible assets, net 5,764 6,182
Deferred income tax asset, net   2,166   2,139
Total assets $ 105,935 $ 97,482
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 2,235 $ 1,644
Accrued expenses   7,780   6,371
Total current liabilities   10,015   8,015
Total liabilities   10,015   8,015
 
Shareholders’ equity:

Preferred stock: authorized 5,000,000 shares of $.01 par  value; none issued or outstanding at both dates

---

---

Common stock: authorized 20,000,000 shares of $.01 par  value; issued and outstanding 11,167,690 and  11,228,654 at October 31, 2011 and October 31,  2010, respectively

112 112
Additional paid-in capital 59,832 61,780
Accumulated other comprehensive (loss) income

(34

)

26
Retained earnings   36,010   27,549
Total shareholders’ equity   95,920   89,467
Total liabilities and shareholders’ equity $ 105,935 $ 97,482
 
SYNOVIS LIFE TECHNOLOGIES, INC.    
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
For the fiscal years ended October 31,   2011     2010  
 
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 8,461 $ 4,876
 
Adjustments to reconcile net income to net cash
provided by operating activities:
 
Depreciation and amortization of property, plant and equipment 1,154 1,228
Amortization of intangible assets 734 782
Amortization of investment premium, net 1,263 1,626
Provision for uncollectible accounts 250 204
Stock-based compensation 1,231 1,455
Tax benefit from stock option exercises (522 ) (296 )
Loss on sale or disposal of property, plant and equipment 25 192
Deferred income taxes (107 ) (117 )
 
Changes in operating assets and liabilities:
Accounts receivable (2,811 ) (1,980 )
Inventories (565 ) (1,709 )
Other current assets (258 ) 40
Accounts payable 591 (318 )
Accrued expenses   1,931     920  
Net cash provided by operating activities   11,377     6,903  
 
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment (1,932 ) (1,102 )
Investments in identifiable intangible assets (316 ) (125 )
Purchases of investments (51,116 ) (79,397 )
Redemptions of investments   50,228     73,618  
Net cash used in investing activities   (3,136 )   (7,006 )
 
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds related to stock-based compensation plans 3,879 1,996
Repurchase of the Company's common stock (7,580 ) (5,101 )
Excess tax benefit of stock option exercises   522     296  
Net cash used in financing activities   (3,179 )   (2,809 )
 
Net change in cash and cash equivalents 5,062 (2,912 )
Cash and cash equivalents at beginning of year   12,951     15,863  
Cash and cash equivalents at end of year $ 18,013   $ 12,951  




1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,186.66 +212.35 1.25%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1250 +16.8990 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs